DNA Bundles for NanoBRET® Target Engagement HDAC and BET BRD Assays

View information on global supply logistics
customize-this-small

For use with the NanoBRET® Target Engagement HDAC and BET BRD Assays

  • DNA Bundle designed for profiling against HDAC or BET BRD proteins in NanoBRET® TE Assay
  • Transfection-ready plasmids
  • Part of the NanoBRET® TE Intracellular HDAC (N2170) and BET BRD (N2180) Complete Kits available for separate purchase

Choose an option

Size

Catalog number selected: N2120

$ 2,365.00
Your price:
Add to Cart
This product is discontinued
This product is available under our Early Access program - Learn More
This product is available under our Catalog (FT) program - Learn More
DNA Bundles for NanoBRET® Target Engagement HDAC and BET BRD Assays
HDAC DNA Bundle/1 each
$ 2,365.00
Your price: Log in
Change Configuration

NanoBRET® Technology for Target Engagement

The NanoBRET® Target Engagement (TE) Intracellular HDAC and BET BRD Assays measure compound binding at select HDAC and BET bromodomain target proteins within intact cells. These target engagement assays are based on the NanoBRET® System, an energy transfer technique designed to measure molecular proximity in living cells. The NanoBRET® TE HDAC and BET BRD Assays analyze the apparent affinity of test compounds by competitive displacement of a NanoBRET® tracer reversibly bound to a NanoLuc® HDAC or BET BRD fusion protein in cells.

The assay uses bioluminescence resonance energy transfer (BRET), achieved by transferring the luminescent energy from NanoLuc® luciferase to the fluorescent tracer that is bound to the target protein-NanoLuc® fusion. This energy transfer makes it possible to directly measure compound binding affinity as well as compound-target residence time.

Compounds that are applied to the cells and specifically engage the intracellular target protein-NanoLuc® fusion will result in a decrease in BRET. To ensure accurate assessment of intracellular target engagement, a NanoLuc® inhibitor is used to mitigate any extracellular NanoLuc® signal that may arise from cells compromised during handling, while not adversely affecting NanoLuc® luciferase expressed within healthy living cells.

DNA Bundle Components

HDAC NanoLuc® Fusion Vectors

13726MA-W
HDAC2 NanoLuc FL Fusion Vector
HDAC3 NanoLuc FL Fusion Vector
NanoLuc HDAC6 FL Fusion Vector
NanoLuc HDAC6 CD2 Fusion Vector
HDAC10 NanoLuc Fusion Vector

BET BRD NanoLuc® Fusion Vectors

13738MA-W
13739MA-W
HDAC10 NanoLuc Fusion Vector
13740MA-W
13741MA-W
13742MA-W
13743MA-W
12900MA-W

Specifications

You are viewing: N2120 Change Configuration

What's in the box?

Item Part # Size

HDAC1-NanoLuc® FL Fusion Vector

N220A 1 × 20μg

HDAC2-NanoLuc® FL Fusion Vector

N221A 1 × 20μg

HDAC3-NanoLuc® FL Fusion Vector

N222A 1 × 20μg

NanoLuc®-HDAC6 FL Fusion Vector

N223A 1 × 20μg

NanoLuc®-HDAC6 CD2 Fusion Vector

N224A 1 × 20μg

HDAC10-NanoLuc® FL Fusion Vector

N225A 1 × 20μg

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide researcher with a full refund.

Researcher may use this product for research use only; no transfer or commercial use of this product is allowed. Commercial use means any and all uses of this product by a party in exchange for consideration, including, but not limited to (1) use in further product manufacture; (2) use in provision of services, information or data; and (3) resale of the product, whether or not such product is resold for use in research. Researcher shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene. No other use of this product is authorized without the prior express written consent of Promega.

In addition, researcher must:
(1a) use Nano-Glo®-branded luminescent assay reagents (LARs) for all determinations of luminescence activity of this product; or
(1b) contact Promega to obtain a license for use of the product with LARs not manufactured by Promega.

For uses of this product (Nano-Glo® ORF Vector) for energy transfer (such as bioluminescence resonance energy transfer), researcher must:
(2a) use NanoBRET®-branded luminescent assay reagents (LARs; e.g., NanoBRET® Nano-Glo® Substrate) or Intracellular TE Nano-Glo® Substrate/Inhibitor for all determinations of luminescent activity; and
(2b) use NanoBRET®-branded energy acceptors (e.g., NanoBRET® tracers, NanoBRET® dyes, BRET-optimized HaloTag® ligands) for all determinations of energy transfer activity; or
(2c) contact Promega to obtain a license for use of the product for energy transfer assays using energy acceptors not manufactured by Promega. No license is needed if the energy transfer acceptor is a genetically encoded autofluorescent protein.

With respect to any uses outside this label license, including any diagnostic, therapeutic, prophylactic or commercial uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH REGARD TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Patent Pending.

U.S. Pat. Nos. 8,557,970, 8,669,103, 9,777,311, 9,840,730, 9,951,373, 10,233,485, 10,633,690, 10,774,364, 10,844,422, 11,365,436, 11,661,623, 11,667,950; European Pat. Nos. 2456864, 2635595, 2990478, 3181687, 3409764; Japanese Pat. Nos. 6038649, 6155424, 6227615, 6374420, 6539689; and other patents and patents pending.

U.S. Pat. Nos. 10,067,149 and 10,024,862, European Pat. No. 2932267, Japanese Pat. Nos. 6751294 and 7092691 and other patents and patents pending.

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,056,885 and 10,139,400, European Pat. No. 2782916 and other patents pending.

Specifications

You are viewing: N2150 Change Configuration

What's in the box?

Item Part # Size

NanoLuc®-BRD4 FL Fusion Vector

N169A 1 × 20μg

NanoLuc®-BRD4 BD1 Fusion Vector

N170A 1 × 20μg

NanoLuc®-BRD3 FL Fusion Vector

N226A 1 × 20μg

NanoLuc®-BRDT FL Fusion Vector

N227A 1 × 20μg

NanoLuc®-BRD2 FL Fusion Vector

N228A 1 × 20μg

NanoLuc®-BRD2 BD1 Fusion Vector

N229A 1 × 20μg

NanoLuc®-BRD2 BD2 Fusion Vector

N230A 1 × 20μg

NanoLuc®-BRD4 BD2 Fusion Vector

N232A 1 × 20μg

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide researcher with a full refund.

Researcher may use this product for research use only; no transfer or commercial use of this product is allowed. Commercial use means any and all uses of this product by a party in exchange for consideration, including, but not limited to (1) use in further product manufacture; (2) use in provision of services, information or data; and (3) resale of the product, whether or not such product is resold for use in research. Researcher shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene. No other use of this product is authorized without the prior express written consent of Promega.

In addition, researcher must:
(1a) use Nano-Glo®-branded luminescent assay reagents (LARs) for all determinations of luminescence activity of this product; or
(1b) contact Promega to obtain a license for use of the product with LARs not manufactured by Promega.

For uses of this product (Nano-Glo® ORF Vector) for energy transfer (such as bioluminescence resonance energy transfer), researcher must:
(2a) use NanoBRET®-branded luminescent assay reagents (LARs; e.g., NanoBRET® Nano-Glo® Substrate) or Intracellular TE Nano-Glo® Substrate/Inhibitor for all determinations of luminescent activity; and
(2b) use NanoBRET®-branded energy acceptors (e.g., NanoBRET® tracers, NanoBRET® dyes, BRET-optimized HaloTag® ligands) for all determinations of energy transfer activity; or
(2c) contact Promega to obtain a license for use of the product for energy transfer assays using energy acceptors not manufactured by Promega. No license is needed if the energy transfer acceptor is a genetically encoded autofluorescent protein.

With respect to any uses outside this label license, including any diagnostic, therapeutic, prophylactic or commercial uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH REGARD TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Patent Pending.

U.S. Pat. Nos. 8,557,970, 8,669,103, 9,777,311, 9,840,730, 9,951,373, 10,233,485, 10,633,690, 10,774,364, 10,844,422, 11,365,436, 11,661,623, 11,667,950; European Pat. Nos. 2456864, 2635595, 2990478, 3181687, 3409764; Japanese Pat. Nos. 6038649, 6155424, 6227615, 6374420, 6539689; and other patents and patents pending.

U.S. Pat. Nos. 10,067,149 and 10,024,862, European Pat. No. 2932267, Japanese Pat. Nos. 6751294 and 7092691 and other patents and patents pending.

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,056,885 and 10,139,400, European Pat. No. 2782916 and other patents pending.

Let's find the product that meets your needs.

Talk to a Scientist

Sylvia

Silvia

Italy